The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Based on developmental psychology and Nietzsche, here's how people become trapped in patterns of appeasement, rebellion, or ...

Most of us have experienced it: a deadline approaches, the task is perfectly doable, yet instead of starting, we suddenly ...

We tend to think of liking and wanting as the same thing. We want what (and who) we like—and vice versa. But what happens ...

Let's look at the pros and cons of going full AI to help you understand how the value and purpose of software development ...

One of the earliest mentions of New Year's resolutions appeared in a Boston newspaper in 1813. But the practice itself can be ...

Dec 8 (Reuters) - Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in ...

One National Guard member died and another was recovering after the attack near the White House on the eve of Thanksgiving. The suspect is a 29-year-old Afghan man. By Francesca Regalado Jin Yu Young ...